MIFEPRISTONE

all catalysts(6)

News(10)

• Trump uses ‘contested’ power to cut more funding to HHS
  Late Friday night, the Trump administration clawed back nearly $1 billion in spending approved by Congress, targeting several HHS programs focused on immigrants and diversity
  stat · 4d ago
• Opinion: FDA commissioner nominee Heidi Overton is ignoring the science on abortion drug
  “With this latest appointment, mifepristone has a new boss but an old problem,” writes Julie F. Kay, founder and CEO of Reproductive Futures.
  stat · 7d ago
• STAT+: Pharmalittle: We’re reading about a reticent FDA commish nominee, a Novo deal, and more
  President Trump’s nominee to lead the FDA was grilled by senators on hot button topics like China, vaccines, and abortion access
  stat · 7d ago
• Federal judge rolls back landmark disability protections
  The Justice Department said in June that it would no longer enforce laws that prioritized people with disabilities living and receiving services in their communities, rather than in nursing homes…
  stat · 7d ago
• FDA nominee Overton parries vaccine questions at Senate hearing
  Pressed by lawmakers on Thursday, Trump’s pick as the next FDA chief said she’d “follow the law” on key decisions and work to speed early drug research.
  biopharma_dive · 8d ago
• STAT+: FDA commissioner nominee Heidi Overton keeps opinions to herself in Senate hearing
  Senators focused on asking Overton about vaccines, abortion, and vapes.
  stat · 8d ago
• US senators grill FDA nominee Overton on ability to ‘stand up’ to Trump
  In Thursday’s Senate committee meeting, FDA commissioner nominee Heidi Overton was repeatedly questioned about her ability to retain the FDA’s independence under President Donald Trump, as well as…
  biospace · 8d ago
• Trump's FDA pick Heidi Overton calls vaccines, mifepristone safe and effective in confirmation hearing
  The Senate Committee on Health, Education, Labor and Pensions (HELP) today questioned Heidi Overton, M.D., Ph.D., Trump’s pick for FDA commissioner, in a hearing marked by tightrope-walking on issu…
  fiercebiotech · 8d ago
• STAT+: Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more
  A major Novartis shareholder has called for a shake-up of the drugmaker's board after its shares suffered a record fall following trial setbacks
  stat · 22d ago
• Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute
  Teva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.
  biopharma_dive · 1mo ago